JP7788399B2 - ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤 - Google Patents

ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤

Info

Publication number
JP7788399B2
JP7788399B2 JP2022566358A JP2022566358A JP7788399B2 JP 7788399 B2 JP7788399 B2 JP 7788399B2 JP 2022566358 A JP2022566358 A JP 2022566358A JP 2022566358 A JP2022566358 A JP 2022566358A JP 7788399 B2 JP7788399 B2 JP 7788399B2
Authority
JP
Japan
Prior art keywords
certain embodiments
alkyl
compound
sorbitol
aldose reductase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022566358A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524504A (ja
JP2023524504A5 (enExample
Inventor
ショーシャナ シェンデルマン，
Original Assignee
アプライド セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプライド セラピューティクス， インコーポレイテッド filed Critical アプライド セラピューティクス， インコーポレイテッド
Publication of JP2023524504A publication Critical patent/JP2023524504A/ja
Publication of JP2023524504A5 publication Critical patent/JP2023524504A5/ja
Priority to JP2025180336A priority Critical patent/JP2026012262A/ja
Application granted granted Critical
Publication of JP7788399B2 publication Critical patent/JP7788399B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022566358A 2020-05-01 2021-04-27 ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤 Active JP7788399B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025180336A JP2026012262A (ja) 2020-05-01 2025-10-27 ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063019186P 2020-05-01 2020-05-01
US63/019,186 2020-05-01
US202063019738P 2020-05-04 2020-05-04
US63/019,738 2020-05-04
PCT/US2021/029286 WO2021222165A1 (en) 2020-05-01 2021-04-27 Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025180336A Division JP2026012262A (ja) 2020-05-01 2025-10-27 ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2023524504A JP2023524504A (ja) 2023-06-12
JP2023524504A5 JP2023524504A5 (enExample) 2024-05-10
JP7788399B2 true JP7788399B2 (ja) 2025-12-18

Family

ID=75954272

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022566358A Active JP7788399B2 (ja) 2020-05-01 2021-04-27 ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤
JP2025180336A Pending JP2026012262A (ja) 2020-05-01 2025-10-27 ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025180336A Pending JP2026012262A (ja) 2020-05-01 2025-10-27 ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤

Country Status (11)

Country Link
US (2) US20230121312A1 (enExample)
EP (1) EP4135674A1 (enExample)
JP (2) JP7788399B2 (enExample)
KR (1) KR20230005944A (enExample)
CN (1) CN115996725A (enExample)
AU (1) AU2021264454A1 (enExample)
BR (1) BR112022021845A2 (enExample)
CA (1) CA3176768A1 (enExample)
IL (1) IL297779A (enExample)
MX (1) MX2022013658A (enExample)
WO (1) WO2021222165A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CA3132136A1 (en) 2019-04-01 2020-10-08 Andrew Wasmuth Inhibitors of aldose reductase
JP2022531466A (ja) 2019-05-07 2022-07-06 ユニバーシティ オブ マイアミ 遺伝性ニューロパチーおよび関連障害の処置および検出
GB202400033D0 (en) 2024-01-02 2024-02-14 Nicolnson Tamara Therapy i
WO2025219948A1 (en) * 2024-04-17 2025-10-23 Assia Chemical Industries Ltd. Crystalline forms of govorestat

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023648A1 (en) 2017-07-28 2019-01-31 Applied Therapeutics Inc. COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA
JP2019518779A (ja) 2016-06-21 2019-07-04 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク アルドース還元酵素阻害剤およびその使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
JPH0495025A (ja) 1990-08-08 1992-03-27 Asahi Chem Ind Co Ltd アルドースリダクターゼ阻害剤
US5464961A (en) 1993-09-10 1995-11-07 Olin Corporation Arcjet anode
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
JPH11512095A (ja) 1995-08-28 1999-10-19 アメリカン・ホーム・プロダクツ・コーポレイション アルドース還元酵素阻害薬および抗高血糖症薬としてのフェノキシ酢酸
PL179170B1 (pl) 1995-09-15 2000-07-31 Inst Lekow Nowe zwiazki,pochodne genisteiny PL PL PL PL
SI0776895T1 (en) 1995-11-20 1999-04-30 Eli Lilly And Company Protein kinase C inhibitor
WO1998042324A2 (en) * 1997-03-21 1998-10-01 The Regents Of The University Of California Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
EP0982306A3 (en) 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
WO2003105864A1 (en) 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
HRP20221430T1 (hr) 2010-07-16 2023-01-06 The Trustees Of Columbia University In The City Of New York Inhibitori aldozoreduktaze i njihova uporaba
WO2017038505A1 (ja) 2015-09-01 2017-03-09 株式会社村田製作所 コイル内蔵部品

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019518779A (ja) 2016-06-21 2019-07-04 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク アルドース還元酵素阻害剤およびその使用方法
WO2019023648A1 (en) 2017-07-28 2019-01-31 Applied Therapeutics Inc. COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA

Also Published As

Publication number Publication date
US20230121312A1 (en) 2023-04-20
BR112022021845A2 (pt) 2022-12-20
JP2023524504A (ja) 2023-06-12
MX2022013658A (es) 2023-03-01
EP4135674A1 (en) 2023-02-22
US20240238288A1 (en) 2024-07-18
IL297779A (en) 2022-12-01
AU2021264454A1 (en) 2022-12-08
CA3176768A1 (en) 2021-11-04
WO2021222165A1 (en) 2021-11-04
KR20230005944A (ko) 2023-01-10
CN115996725A (zh) 2023-04-21
JP2026012262A (ja) 2026-01-23

Similar Documents

Publication Publication Date Title
JP7788399B2 (ja) ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤
JP7778686B2 (ja) ホスホマンノムターゼ２欠損の処置のためのアルドースレダクターゼ阻害剤
JP7541064B2 (ja) ガラクトース血症を処置するための組成物および方法
US20220071880A1 (en) Methods for treating cutaneous aging
RU2858535C2 (ru) Ингибиторы альдозоредуктазы для лечения дефицита сорбитолдегидрогеназы
BR122025019642A2 (pt) Uso de inibidores de aldose redutase para tratar deficiência em sorbitol desidrogenase
HK40113967A (en) Compositions and methods for treating galactosemia
RU2830187C2 (ru) Композиции и способы лечения галактоземии
HK40030466B (en) Compositions and methods for treating galactosemia
BR112020001755B1 (pt) Usos de um inibidor da aldose redutase para o tratamento de galactosemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251027

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251208

R150 Certificate of patent or registration of utility model

Ref document number: 7788399

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150